Table 2.
Cox regression for disease-free survival, 48 events amongst 180 patients
| N | Outcome |
Unadjusted (n=180) |
Adjusted (n=176) |
Stepwise† (n=176) |
|||||
|---|---|---|---|---|---|---|---|---|---|
| n (%) | Rate∗ | HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| TEA | 89 | 21 (23.6) | 5.9 | Reference | Reference | Reference | |||
| PCA | 91 | 27 (29.7) | 7.8 | 1.31 (0.74–2.32) | 0.35 | 1.19 (0.61–2.31) | 0.61 | 1.15 (0.61–2.15) | 0.66 |
| Age (yr) | |||||||||
| <65 | 63 | 18 (28.6) | 7.4 | Reference | Reference | Reference | |||
| 65 to <75 | 80 | 14 (17.5) | 4.3 | 0.59 (0.29–1.16) | 0.14 | 0.70 (0.32–1.50) | 0.36 | 0.80 (0.38–1.64) | 0.54 |
| ≥75 | 37 | 16 (43.2) | 12.5 | 1.67 (0.85–3.28) | 0.13 | 2.30 (1.03–5.16) | 0.042 | 2.14 (1.07–4.27) | 0.032 |
| Sex | |||||||||
| Women | 65 | 15 (23.1) | 5.6 | Reference | Reference | Reference | |||
| Men | 115 | 33 (28.7) | 7.6 | 1.36 (0.74–2.50) | 0.29 | 2.04 (1.00–4.14) | 0.049 | 1.68 (0.87–3.22) | 0.12 |
| Study centre | |||||||||
| Örebro | 90 | 16 (17.8) | 4.4 | Reference | Reference | Reference | |||
| Linköping | 80 | 30 (37.5) | 10.1 | 2.27 (1.24–4.17) | 0.008 | 1.62 (0.80–3.29) | 0.18 | 1.70 (0.91–3.17) | 0.096 |
| Karlstad | 10 | 2 (20.0) | 4.5 | 1.02 (0.23–4.45) | 0.98 | 0.49 (0.10–2.37) | 0.38 | 0.65 (0.14–2.96) | 0.58 |
| Type of cancer | |||||||||
| Rectal | 98 | 26 (26.5) | 6.6 | Reference | Reference | ||||
| Colon | 82 | 22 (26.8) | 7.1 | 1.05 (0.60–1.86) | 0.86 | 1.53 (0.60–3.85) | 0.37 | ||
| Type of surgery | |||||||||
| Laparoscopic | 76 | 13 (17.1) | 4.2 | Reference | Reference | ||||
| Open/converted | 104 | 35 (33.6) | 8.9 | 2.07 (1.09–3.91) | 0.025 | 1.23 (0.59–2.56) | 0.58 | ||
| BMI (kg m−2) | |||||||||
| <25 normal | 67 | 20 (29.8) | 7.6 | Reference | Reference | ||||
| 25 to <30 pre-obesity | 81 | 20 (24.7) | 6.3 | 0.83 (0.45–1.55) | 0.57 | 0.84 (0.42–1.71) | 0.64 | ||
| ≥30 obesity | 32 | 8 (25.0) | 6.7 | 0.89 (0.39–2.03) | 0.78 | 1.18 (0.46–3.01) | 0.73 | ||
| ASA physical status | (n=179) | ||||||||
| 1 | 53 | 13 (24.5) | 6.1 | Reference | Reference | ||||
| 2 | 107 | 30 (28.0) | 7.3 | 1.17 (0.61–2.24) | 0.64 | 0.78 (0.37–1.65) | 0.52 | ||
| 3 | 19 | 5 (26.3) | 6.8 | 1.13 (0.40–3.18) | 0.81 | 0.82 (0.23–2.88) | 0.75 | ||
| T stage | (n=179) | ||||||||
| T0/T1//T2 | 45 | 3 (6.7) | 1.5 | Reference | Reference | Reference | |||
| T3 | 113 | 33 (29.2) | 7.5 | 5.00 (1.53–16.3) | 0.008 | 3.00 (0.84–10.8) | 0.091 | 3.57 (1.06–12.0) | 0.040 |
| T4 | 21 | 12 (57.1) | 22.6 | 13.7 (3.85–48.7) | <0.001 | 5.84 (1.23–27.6) | 0.026 | 7.51 (2.01–28.0) | 0.003 |
| N stage | |||||||||
| N0 | 105 | 15 (14.3) | 3.4 | Reference | Reference | Reference | |||
| N1 | 52 | 22 (42.3) | 12.1 | 3.45 (1.79–6.66) | <0.001 | 1.90 (0.81–4.44) | 0.14 | 2.48 (1.22–5.03) | 0.012 |
| N2 | 23 | 11 (47.8) | 15.2 | 4.26 (1.95–9.28) | <0.001 | 2.21 (0.89–5.50) | 0.088 | 3.13 (1.38–7.08) | 0.006 |
| Preoperative radiotherapy | 66 | 21 (31.8) | 8.2 | 1.34 (0.76–2.38) | 0.31 | 1.76 (0.73–4.25) | 0.21 | ||
| Adjuvant treatment | (n=178) 79 | 33 (41.8) | 11.9 | 3.12 (1.70–7.76) | <0.001 | 1.73 (0.67–4.49) | 0.26 | ||
∗
Rates, number of events per 100 person-years.
†
Backward stepwise regression with significance level of 0.20.